MeiraGTx Swings to $160.7M Q2 Profit, Acquires Bota-vec, and Secures FDA Breakthrough Designation
MGTX has more than doubled off its 52-week low of $6.62 on light trading volume (0.3× avg).
Summary
MeiraGTx reported a $160.7M Q2 profit, a dramatic swing from prior losses, driven by the acquisition of bota-vec from J&J for $25M upfront. The company also received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in radiation-induced xerostomia and completed enrollment in the pivotal Phase 2 AQUAx2 study. Management is building commercial infrastructure ahead of potential launches in 2027, with two senior J&J veterans joining the leadership team. This follows the $400M Oberland Capital investment in July and the FDA IND clearance for GV101 earlier this week. The profit and regulatory milestones mark a transition toward commercialization, but the sustainability of the profit and the timing of regulatory filings remain key watchpoints.
At the time of this announcement, MGTX was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.62 to $15.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.